AC Immune SA reports results for the quarter ended in September 30 - Earnings Summary

AC Immune SA

06/11/2024 05:20

* AC Immune SA  ACIU.OQ  reported quarterly adjusted
earnings of 5
rappen​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of -18 rappen.  The mean expectation of four analysts for the
quarter was for a loss of 20 rappen per share. Wall Street
expected results to range from -20 rappen to -19 rappen per
share.
    * Revenue was CHF25.49 million​; analysts expected $1.48
million. 
    * AC Immune SA's reported EPS for the quarter was 5 rappen​.
    * The company reported quarterly net income of $5.5 million.
    * AC Immune SA shares had fallen by 14.3% this quarter and
lost 35.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for AC Immune SA is
$8.50 
This summary was machine generated from LSEG data November 6 at
05:19 a.m. UTC. ​All figures in Swiss francs unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.20          0.05           Beat
 Jun. 30 2024      0.27           -0.23          Missed
 Mar. 31 2024      -0.14          -0.18          Missed
 Dec. 31 2023      -0.11          -0.05          Beat